Other Events ·
FDA grants Orphan Drug Designation to HUTCHMED's sovleplenib for primary immune thrombocytopenia
HCMHUTCHMED (China) Ltd
The US Food and Drug Administration has granted Orphan Drug Designation to HUTCHMED's investigational drug sovleplenib for the treatment of primary immune thrombocytopenia (ITP). This designation recognizes the drug's potential to address significant unmet medical needs in patients with this rare autoimmune disorder. If approved, the drug becomes eligible for development incentives including seven years of US market exclusivity upon regulatory approval, tax credits for qualified clinical trials, and user fee waivers under the Prescription Drug User Fee Act. HUTCHMED is an innovative biopharmaceutical company focused on the discovery and global commercialization of targeted therapies and immunotherapies for cancer and immunological diseases.